Conivaptan
- Generic Name
- Conivaptan
- Brand Names
- Vaprisol
- Drug Type
- Small Molecule
- Chemical Formula
- C32H26N4O2
- CAS Number
- 210101-16-9
- Unique Ingredient Identifier
- 0NJ98Y462X
- Background
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
- Indication
For the treatment of euvolemic or hypervolemic hyponatremia (e.g. the syndrome of inappropriate secretion of antidiuretic hormone, or in the setting of hypothyroidism, adrenal insufficiency, pulmonary disorders, etc.) in hospitalized patients.
- Associated Conditions
- Euvolemic Hyponatremia, Hypervolemic Hyponatremia
- Associated Therapies
- -
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE ...
Cumberland Pharmaceuticals announced FDA granted Orphan Drug and Rare Pediatric Disease Designations to Ifetroban for treating cardiomyopathy in Duchenne muscular dystrophy (DMD). The FIGHT DMD™ trial, a Phase II study, is investigating Ifetroban's safety and efficacy in DMD patients, with results expected later this year.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath